Shannon J. Ho,Dale Chaput,Rachel G. Sinkey,Amanda H. Garces,Erika P. New,Maja Okuka,Peng Sang,Sefa Arlier,Nihan Semerci,Thora S. Steffensen,Thomas J. Rutherford,Angel E. Alsina,Jianfeng Cai,Matthew L. Anderson,Ronald R. Magness,Vladimir N. Uversky,Derek A. T. Cummings,John C. M. Tsibris
Abstract:VEGFR2 (Vascular endothelial growth factor receptor 2) is a central regulator of placental angiogenesis. The study of the VEGFR2 proteome of chorionic villi at term revealed its partners MDMX (Double minute 4 protein) and PICALM (Phosphatidylinositol-binding clathrin assembly protein). Subsequently, the oxytocin receptor (OT-R) and vasopressin V1aR receptor were detected in MDMX and PICALM immunoprecipitations. Immunogold electron microscopy showed VEGFR2 on endothelial cell (EC) nuclei, mitochondria, and Hofbauer cells (HC), tissue-resident macrophages of the placenta. MDMX, PICALM, and V1aR were located on EC plasma membranes, nuclei, and HC nuclei. Unexpectedly, PICALM and OT-R were detected on EC projections into the fetal lumen and OT-R on 20–150 nm clusters therein, prompting the hypothesis that placental exosomes transport OT-R to the fetus and across the blood–brain barrier. Insights on gestational complications were gained by univariable and multivariable regression analyses associating preeclampsia with lower MDMX protein levels in membrane extracts of chorionic villi, and lower MDMX, PICALM, OT-R, and V1aR with spontaneous vaginal deliveries compared to cesarean deliveries before the onset of labor. We found select associations between higher MDMX, PICALM, OT-R protein levels and either gravidity, diabetes, BMI, maternal age, or neonatal weight, and correlations only between PICALM-OT-R ( p < 2.7 × 10 –8 ), PICALM-V1aR ( p < 0.006), and OT-R-V1aR ( p < 0.001). These results offer for exploration new partnerships in metabolic networks, tissue-resident immunity, and labor, notably for HC that predominantly express MDMX.
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is to study the role of vascular endothelial growth factor receptor 2 (VEGFR2) in the human placenta through proteomics and its association with pregnancy complications (such as pre - eclampsia, diabetes, parity, and mode of delivery). Specifically, the researchers hope to identify new partner proteins of VEGFR2 through techniques such as immunoprecipitation and mass spectrometry analysis, and explore the differences in the expression of these partner proteins in normal and complicated pregnancies, as well as their potential roles in the metabolic network, tissue - resident immunity, and the process of delivery.
### Research Background
The placenta is a temporary organ that undertakes the functions of multiple major organs of the fetus, such as the lungs, liver, and kidneys. It provides oxygen and nutrients to the fetus, helps with waste excretion, and provides immune protection. VEGF - A (vascular endothelial growth factor A) is a key molecule that regulates angiogenesis, neovascularization, and placental growth, mainly acting through two single - transmembrane tyrosine kinase receptors, VEGFR1 and VEGFR2.
### Pre - eclampsia
Pre - eclampsia is a serious pregnancy complication, with an incidence of approximately 5 - 7%. Its main clinical features are new - onset hypertension and proteinuria. Pre - eclampsia is a multi - system syndrome that has long - term impacts on the health of the mother and fetus.
### Exosomes
Cell - extracellular vesicles (EVs) wrapped by lipid bilayers can transport extracellular nucleic acids, proteins, lipids, and metabolites. Exosomes are a type of EV with a diameter of 20 - 150 nanometers. Placenta - derived exosomes are released into the maternal circulation and are related to pregnancy disorders and delivery.
### Proteomics
Although human proteome maps of multiple organs (including the placenta) have been published, there are still challenges in discovering which of the hundreds of detected proteins regulate key metabolic networks, especially during normal and complicated pregnancies and delivery.
### Research Methods
To obtain this information, the researchers chose to immunoprecipitate VEGFR2, a known regulator of placental angiogenesis. By analyzing the precipitate after high - speed centrifugation of placental villus homologues, the researchers extracted protein complexes using ASB - 14 and identified proteins co - immunoprecipitated with VEGFR2 through mass spectrometry analysis.
### Main Findings
- **New Partner Proteins**: The researchers discovered new partner proteins of VEGFR2, including MDMX and PICALM.
- **Protein Localization**: Through immunogold electron microscopy, the researchers found that VEGFR2 is located on endothelial cell nuclei, mitochondria, and Hofbauer cells (placental tissue - resident macrophages). MDMX, PICALM, and V1aR are located on endothelial cell plasma membranes, nuclei, and Hofbauer cell nuclei.
- **Clinical Association**: Through univariate and multivariate regression analyses, the researchers found that the MDMX protein level in placental chorionic extracts of pre - eclampsia patients is lower, while the MDMX, PICALM, OT - R, and V1aR protein levels in patients with spontaneous vaginal delivery are lower. In addition, a selective association was also found between higher MDMX, PICALM, OT - R protein levels and parity, diabetes, BMI, maternal age, or neonatal weight.
- **Protein - Protein Interaction**: The researchers found significant correlations among PICALM - OT - R, PICALM - V1aR, and OT - R - V1aR.
### Conclusion
These results provide clues for exploring new partnerships in the metabolic network, tissue - resident immunity, and the process of delivery, especially for Hofbauer cells that mainly express MDMX. These findings may contribute to the development of new treatment strategies, especially in the management of pre - eclampsia and other pregnancy complications.